GB1473148A - - Google Patents
Info
- Publication number
- GB1473148A GB1473148A GB4017574A GB4017574A GB1473148A GB 1473148 A GB1473148 A GB 1473148A GB 4017574 A GB4017574 A GB 4017574A GB 4017574 A GB4017574 A GB 4017574A GB 1473148 A GB1473148 A GB 1473148A
- Authority
- GB
- United Kingdom
- Prior art keywords
- deoxyribosyl
- ribosyl
- phosphates
- diaquodiammineplatinum
- alkylribosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 235000021317 phosphate Nutrition 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- XXESGWORFDGSQY-UHFFFAOYSA-N azane;platinum(2+);dihydrate Chemical compound N.N.O.O.[Pt+2] XXESGWORFDGSQY-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- -1 ribosyl phosphates Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1473148 Platinum-containing derivatives of uracil RESEARCH CORP 16 Sept 1974 40175/74 Heading C2C The invention comprises complexes prepared by reacting at 0-55‹ C., 1 mole of cis-diaquodiammineplatinum (II) with 1-2 moles of a compound of formula or its 5,6-dihydro derivative, wherein R 1 and R 2 are each H, alkyl, dialkylamino, di(haloalkyl)- amino, halogen, OH, hydroxyalkyl or carboalkoxy, and R 3 and R 4 are each H, alkylribosyl, deoxyribosyl, ribosyl, triacetyl-, tribenzoyl- or 2<SP>1</SP>,3<SP>1</SP>-alkylideneribosyl, ribosyl phosphates or deoxyribosyl phosphates. Therapeutic compositions for treating cancer or bacterial or viral infections comprise the above complexes, and may be administered orally or parenterally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB4017574A GB1473148A (en) | 1974-09-16 | 1974-09-16 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB4017574A GB1473148A (en) | 1974-09-16 | 1974-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1473148A true GB1473148A (en) | 1977-05-11 |
Family
ID=10413576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB4017574A Expired GB1473148A (en) | 1974-09-16 | 1974-09-16 |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1473148A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
WO1996023506A1 (en) * | 1995-02-01 | 1996-08-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Use of 5'substituted nucleosides to provide resistance in cytostatic treatment and medicaments containing said nucleosides |
US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US7122528B2 (en) | 2001-02-23 | 2006-10-17 | Resprotect Gmbh | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
US7776838B1 (en) | 1987-10-28 | 2010-08-17 | Wellstat Therapeutics Corporation | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
-
1974
- 1974-09-16 GB GB4017574A patent/GB1473148A/en not_active Expired
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316426B1 (en) | 1987-10-28 | 2001-11-13 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US6258795B1 (en) | 1987-10-28 | 2001-07-10 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
US6274563B1 (en) | 1987-10-28 | 2001-08-14 | Pro-Neuron, Inc. | Acylated uridine and cytidine and uses thereof |
US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
US6344447B2 (en) | 1987-10-28 | 2002-02-05 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US7105498B2 (en) | 1987-10-28 | 2006-09-12 | Wellstat Therapeutics Corporation | Acylated uridine and cytidine and uses thereof |
US7166581B1 (en) | 1987-10-28 | 2007-01-23 | Wellstat Therapeutics Corporation | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US7776838B1 (en) | 1987-10-28 | 2010-08-17 | Wellstat Therapeutics Corporation | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
WO1996023506A1 (en) * | 1995-02-01 | 1996-08-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Use of 5'substituted nucleosides to provide resistance in cytostatic treatment and medicaments containing said nucleosides |
US6589941B1 (en) | 1995-02-01 | 2003-07-08 | Resprotect Gmbh | Utilization of 5′ substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions |
US7122528B2 (en) | 2001-02-23 | 2006-10-17 | Resprotect Gmbh | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1132082A (en) | The manufacture of pyrimidine derivatives | |
AU565168B2 (en) | 4:-demethyl - 4 - epipodophyllotoxin derivatives | |
AU554227B2 (en) | Vicinal dihydroxyalkylxanthine derivatives | |
GB1145789A (en) | New n-aralkyl-adenosine derivatives | |
ES476109A1 (en) | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions and their preparation. | |
ES460040A1 (en) | 4-hydroxyphenylalkanolamine derivatives and preparation thereof | |
ES8706654A1 (en) | Benzothiazine derivatives. | |
NZ308398A (en) | 2-amino benzoxazin-4-one derivatives and medicaments | |
NO922148L (en) | ||
GB1473148A (en) | ||
ES447011A1 (en) | Anti-diarrheal compounds | |
GB1290818A (en) | ||
GB1130956A (en) | Substituted pteridines and pharmaceutical compositions containing them | |
AU571206B2 (en) | 6-hydroxyalkyl-penem derivatives | |
GB1229082A (en) | ||
ES8401926A1 (en) | Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same. | |
ES8502435A1 (en) | 2(1H)-pyridinones, useful as cardiotonic agents, and their production. | |
ES8507472A1 (en) | New compounds, pharmaceutical preparations containing same and process for their preparation. | |
ES8404373A1 (en) | Novel 2-beta-D-ribofuranosylselenazole-4-carboxamide compounds and methods for their production. | |
MY106512A (en) | Process for the preparation of 6-(substitutedaminopro- pionyl)-derivatives of fokskolin. | |
GB1357733A (en) | 1,2,4-oxadiazole derivatives | |
GB1148288A (en) | A process for the manufacture of benzdiaz[1,4]epine derivatives | |
GB1088102A (en) | Halogen substituted pyrido-pyrimidines | |
ES8308335A1 (en) | Antiviral deoxyuridine compounds. | |
GB1173309A (en) | The Manufacture of Benzdiaz[1,4]Epine Derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |